Targovax ASA logo

TRVX - Targovax ASA News Story

NOK6.36 -0.1  -1.4%

Last Trade - 1:02pm

Sector
Healthcare
Size
Micro Cap
Market Cap £41.8m
Enterprise Value £36.1m
Revenue £218k
Position in Universe 1007th / 1781

BRIEF-Targovax And IOVaxis Enter Option Agreement For TG Mutant RAS Vaccine License And Clinical Development In China

Wed 8th January, 2020 6:45am
Jan 8 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX AND IOVAXIS THERAPEUTICS ENTERS OPTION AGREEMENT
FOR TG
MUTANT RAS VACCINE LICENSE AND CLINICAL DEVELOPMENT IN CHINA
    * IOVAXIS BUYS AN EXCLUSIVE OPTION TO LICENSE TG01/02 CANCER
VACCINES FOR CHINA, HONG KONG, MACAU AND SINGAPORE, FOR A FEE OF
USD 250.000
    * IF EXERCISED, LICENSE HAS A POTENTIAL VALUE OF UP TO USD
100
MILLION IN DEVELOPMENT AND COMMERCIAL MILESTONES, IN ADDITION TO
DOUBLE-DIGIT ROYALTIES
    * PARTIES WILL NEGOTIATE A FULL LICENSE AGREEMENT BASED ON
PRE-AGREED TERMS AND PRINCIPLES IN OPTION AGREEMENT
    * FULL LICENSE AGREEMENT REMAINS TO BE FINALIZED, BUT
PARTIES HAVE
PRE-AGREED KEY COMMERCIAL AND OPERATIONAL TERMS IN OPTION
AGREEMENT
    * IF EXERCISED, TOTAL POTENTIAL DEVELOPMENT AND COMMERCIAL
MILESTONES FOR TG01/02 LICENSE MAY REACH UP TO USD 100 MILLION,
PLUS TIERED ROYALTIES ON NET SALES UP TO MID DOUBLE DIGITS.

Source text for Eikon:  ID:nWkr2fxJxf 
Further company coverage:  TRVX.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.